Company: SGBAF
Filing Date: 2025-04-01
Form Type: DRS/A
Source: 0000950123-25-003272
Chunk: 256

Company: SES S.A.
Filing Date: 2025-04-01
Form: DRS/A
Chunk 256
---
 Treatment Requested by SES Pursuant to 17 C.F.R. Section 200.83

| (6) | Ownership information for Intelsat common shares is as of February 23, 2022. The address for these shareholders 
 is 1 E Ohio St., Floor 06 Indianapolis, IN 46204.                                                               |

| (7) | Consists of 3,786,782 Intelsat common shares and warrants to purchase 472 Intelsat common shares. Ownership                                                   
 information of warrants to purchase Intelsat common shares is as of February 23, 2022. The address for these shareholders is P.O. Box 32339 Newark, NJ 07102. |

| (8) | Consists of 3,704,083 Intelsat common shares and warrants to purchase 20 Intelsat common shares. Ownership                                                              
 information of warrants to purchase Intelsat common shares is as of February 23, 2022. The address for these shareholders is 865 S. Figueroa St. Los Angeles, CA 90017. |

| (9) | As manager of CVI General Partner, LLC, the director or general partner of the CarVal Shareholders, as                                                                                                                                 
 applicable, Mr. Simpson may be deemed to beneficially own the 5,024,830 Intelsat common shares held of record by the CarVal Shareholders. Mr. Simpson disclaims beneficial ownership of such Intelsat common shares held by the CarVal 
 Shareholders.                                                                                                                                                                                                                          |

184

Confidential Treatment Requested by SES Pursuant to 17 C.F.R. Section 200.83 BOARD OF DIRECTORS / MANAGEMENT OF SES FOLLOWING THE ACQUISITION Executive Officers and Directors The following table sets forth the name, age and position of each of the individuals who are expected to initially serve as executives and directors of the Combined Group as of March 21, 2025.

| Name                         |     | Age |    |     | Position                                                                    |
| Executive Committee Members: |     |     |    |     |                                                                             |
| Adel Al-Saleh                |     |     | 61 |     | CEO                                                                         |
| Dr. Xavier Bertrán           |     |     | 52 |     | Chief Product & Innovation Officer                                          |
| John-Paul Hemingway          |     |     | 52 |     | Chief Commercial Officer                                                    |
| Veronika Ivanovic            |     |     | 53